Temozolomide Hexal is used for specific therapeutic indications in oncology. This medicine is used for managing malignant glioma, an aggressive type of brain tumor, in both adults and children from three years of age with recurrent disease. It is commonly used to address conditions characterized by periods of heightened symptoms, specifically Glioblastoma multiforme (GBM) and Anaplastic Astrocytoma (AA).

The treatment is applied in addressing these high-grade malignancies, particularly in scenarios where symptoms may intensify temporarily. It is used as part of a comprehensive strategy, often alongside radiotherapy, where it supports the patient during difficult episodes by easing distress. This medication assists with maintaining functional stability and may assist with maintaining a sense of stability when symptoms are more noticeable, providing support that helps ease the long-term burden of this serious illness. The primary focus is on managing the condition across therapeutic contexts.

“This treatment is considered relevant for patients with newly diagnosed Glioblastoma multiforme when combined with radiotherapy.”

Quick Fact: Relief for Symptom Burden (This medication plays a role in managing the overall condition, which may include preventing relapse.)

Eligibility and Non-Eligibility for Temozolomide Hexal

The official regulatory documents define who can and cannot use Temozolomide Hexal based on three primary factors: hypersensitivity, blood cell counts, and age.

The medicine is strictly contraindicated for patients with a history of hypersensitivity or allergic reaction to the active substance, temozolomide, or to the related anticancer agent dacarbazine (DTIC), or any of its inactive components. Use is also contraindicated in patients with severe myelosuppression—a significant reduction in the bone marrow's production of blood cells.

Population Status	Eligibility Rule (Official)
Allowed Populations	Adults with newly-diagnosed glioblastoma multiforme or adults and children 3 years of age and older with recurrent or progressive malignant glioma.
Contraindicated	Hypersensitivity to temozolomide or dacarbazine; Pre-existing severe myelosuppression.
Restricted Use	The start of each treatment cycle requires laboratory confirmation of an Absolute Neutrophil Count (ANC) ge 1.5 imes 10^9/L and a Platelet count ge 100 imes 10^9/L.

Pregnancy and Lactation: The drug can cause fetal harm, and females of reproductive potential must use effective contraception during and shortly after treatment. Use is not recommended for nursing mothers. Caution is advised for patients with severe renal or hepatic impairment, and elderly patients (over 70) may have an increased risk of blood count reduction.

Interactions with other medicines and products

Temozolomide Hexal's official regulatory profile for interactions primarily addresses three areas: administration requirements, pharmacodynamic additive toxicity, and the medicine's unique metabolic pathway.

Pharmacokinetic and Metabolic Interactions

The conversion of temozolomide to its active substance occurs through spontaneous, non-enzymatic hydrolysis at physiological pH. As a result, the clearance of Temozolomide is officially documented as not affected by the co-administration of commonly used medicines, including dexamethasone, phenytoin, phenobarbital, and certain H2-receptor antagonists. Co-administration with Valproic Acid results in a small, clinically non-significant decrease in the medicine’s clearance.

Pharmacodynamic Interactions

Additive Toxicity: Concomitant use with other medicinal products that are known to cause myelosuppression (such as certain anti-seizure medicines and antibiotics) may complicate the assessment of hematologic toxicity and increase the risk of severe neutropenia and thrombocytopenia. This risk is also documented as increased in elderly patients over 70 years of age.

Infection Risk: Co-administration with corticosteroids increases the patient’s susceptibility to opportunistic infections, necessitating specific infection prophylaxis protocols during certain treatment regimens.

Interaction-Related Restrictions

Drug-Food Interaction: Temozolomide Hexal is subject to a critical timing rule: it must be administered in the fasting state. Administration with food causes a documented reduction in the medicine's absorption, specifically reducing the maximum plasma concentration ( C max) and overall exposure ( AUC).

How Temozolomide Hexal Works

---

DNA Alkylation and Genotoxic Stress

The molecule functions as a prodrug that undergoes rapid, spontaneous conversion into its active intermediate, MTIC, within physiological fluid. This intermediate is an alkylating agent that directly adds a methyl group to the DNA inside cells, primarily targeting the O^6 and N^7 positions of guanine bases. This covalent modification introduces a severe lesion to the genetic code, initiating a cascade of genotoxic stress that disrupts the structural integrity required for DNA replication.

---

Pathway Exploitation and Cytotoxicity

The mechanism of action relies on the cell’s own Mismatch Repair (MMR) pathway attempting to correct the drug-induced lesions. This attempted repair is futile and results in overwhelming DNA double-strand breaks, forcing the cell into G2/M phase cell cycle arrest. The accumulation of irreparable damage triggers the programmed cell death (apoptosis) pathway, leading to cellular cytotoxicity and the systemic anti-proliferative consequence.

---

Mechanistic Constraint by MGMT

The efficacy of the alkylation mechanism is significantly constrained by the enzyme O^6-methylguanine-DNA methyltransferase (MGMT). When present, MGMT acts as a direct counter-mechanism, removing the critical methyl group from the DNA target before the lethal MMR cascade can fully engage, thereby modulating the resulting anti-proliferative effect.

Temozolomide is administered following a Body Surface Area (BSA)-based dosing protocol and strictly defined cyclic schedules, as outlined in official labeling. The medicine can be administered by the oral route via capsules or, where available, by intravenous (IV) infusion over 90 minutes; the dose is identical for both routes.

Administration and Timing

Procedural Condition	Official Instruction
Route of Administration	Oral capsules or 90-minute IV infusion.
Timing in Relation to Meals	Must be taken once daily in the fasting state (e.g., on an empty stomach or at bedtime).
Capsule Handling	Capsules must be swallowed whole with water. They must not be opened, chewed, or dissolved.

Dosing Schedule and Monitoring

Treatment follows two phases: the concomitant phase (daily for 42–49 days alongside radiotherapy) and the maintenance phase (6 cycles). The maintenance phase involves taking the dose for 5 consecutive days followed by a 23-day break, constituting a 28-day cycle.

Dose modifications for subsequent cycles are mandatory and strictly governed by blood count criteria. A new cycle must not be initiated unless the Absolute Neutrophil Count (ANC) is ge 1.5 imes 10^9/L and the Platelet Count is ge 100 imes 10^9/L. If a dose is missed, it should be taken as soon as possible on the same day, but a double dose must never be taken to compensate for a missed dose.

Research evidence / Overview of studies for Temozolomide Hexal

---

Evidence for use in Newly Diagnosed Glioblastoma

This section will summarize the key clinical studies—primarily randomized controlled trials—that evaluated Temozolomide Hexal (or the original brand, as a generic) when used alongside radiation therapy for patients with newly diagnosed glioblastoma, followed by maintenance treatment.

Research has extensively explored the use of this medication as part of the initial treatment plan for glioblastoma that has recently been diagnosed. Studies monitored patients receiving the standard combination of Temozolomide with radiation therapy, and then continued follow-up with the drug alone for a set time. The research specifically examined outcomes related to systemic or functional imbalance and the patterns of change in the condition observed in the populations studied.

Findings from the central randomized trials describe patterns related to measures of time to progression and survival measures reported in the populations studied, where the comparator was radiation alone. Specifically, studies report how the condition evolved in the observed populations, and this evidence contributes to understanding symptom patterns over time. The results apply only to the populations studied and do not determine whether an individual will respond similarly.

---

Evidence for use in Anaplastic Astrocytoma

This part will outline the research evidence, including phase 2 and 3 trials, that supports the use of Temozolomide Hexal for adults with anaplastic astrocytoma, detailing how studies addressed both newly diagnosed and recurrent (returned) disease.

Temozolomide Hexal was also studied for adults with anaplastic astrocytoma, which is a condition involving periods of heightened symptoms. Studies explored its use both as an initial treatment and for patients whose condition had returned after previous therapy. In these research contexts, scientists observed outcomes related to physical discomfort and changes measured during the study period.

For newly diagnosed anaplastic astrocytoma, research has examined the drug's role both alone and in combination with radiation. Evidence describes patterns related to measures of time without progression reported in the populations studied. For recurrent disease, evidence is limited and studies monitored patients who were experiencing temporary physiological imbalance to see how symptoms evolved. Findings help contextualize how patients reported their experience, but comparative evidence is lacking.

---

Long-term Studies and Follow-up

This segment will synthesize data from studies that have monitored patients for extended periods to understand the long-term outcomes after treatment, including the durability of response and what is known about patient survival several years after starting the therapy.

Research has explored the effects of Temozolomide Hexal beyond the initial treatment phase. These long-term studies monitored patient-reported outcomes describing perceived discomfort and stability over defined time intervals, sometimes spanning several years. This follow-up data show patterns related to the durability of the initial responses reported in the groups studied.

While these studies contribute to the broader evidence landscape, it is important to note that long-term effects are not fully established, and there is limited information for outcomes many years after stopping the medication. Follow-up durations were limited in the primary trials, and the data for certain groups remain insufficient, meaning certainty remains low regarding outcomes far into the future.

---

Evidence in Special Populations

This section will summarize studies that have specifically evaluated the use of Temozolomide Hexal in patients who may respond differently to treatment, such as children and adolescents, older adults, or those with other significant existing health conditions.

Studies examined the use of the medication in specific patient populations. For example, research has examined its use in children and adolescents, but studies focusing on episodes where symptoms become more noticeable in this group often have sample sizes that were modest, meaning current data are limited and certainty remains low.

For older adults, studies have been conducted during periods of increased symptom activity to understand how the drug is tolerated and how it was associated with outcomes reflecting daily functioning or activity level. Findings were mixed in some of these groups, and evidence quality varies across studies, suggesting that the results apply only to the specific populations studied.

---

What is Still Uncertain about Temozolomide Hexal

This final part will clearly synthesize the main evidence gaps and unanswered questions in the medical literature, clarifying areas where clinical studies show inconsistent results or where more research is needed to fully understand the drug's role.

Despite the research that has been conducted, there are several areas where the evidence remains insufficient. For instance, more research is ongoing to understand the best approach for managing patients with conditions characterized by fluctuating or episodic manifestations while on this treatment.

Data for certain subgroups, such as those with specific genetic markers or very rare forms of the disease, remain insufficient, and comparative evidence against certain newer treatments is lacking. While studies provide insight into short-term changes and findings describe group patterns, not personal outcomes, the main evidence gaps involve long-term follow-up and the lack of robust data for certain specific patient groups.

Key Studies & References The use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour Consortium

Common questions about Temozolomide Hexal (FAQ)

---

Q: How quickly does Temozolomide Hexal start working?

A: Official product information, which details how the medicine is processed by the body (pharmacokinetics), indicates that Temozolomide Hexal is rapidly absorbed after taking the capsule. The medicine typically reaches its maximum concentration (Cmax) in the blood within about one hour. This indicates that the active substance is rapidly made available in the body for its systemic action.

Q: How is Temozolomide Hexal different from other chemotherapy drugs?

A: Temozolomide Hexal is classified as an alkylating agent, which is a specific type of antineoplastic medicine. Its mechanism involves directly modifying the DNA inside cells, a process that relies on the cell's own repair systems to trigger cell death. Official documents further classify it as an Imidazotetrazine derivative.

Q: Can Temozolomide Hexal affect my ability to drive?

A: Regulatory documents state that this medicine may cause side effects such as fatigue or drowsiness. If these effects occur, official labeling states that engaging in activities requiring alertness, such as driving or using tools or heavy machinery, should be avoided until one is aware of the medicine's effects.

Q: Does Temozolomide Hexal come in different strengths?

A: Yes, regulatory and official dosage form information indicates that Temozolomide Hexal is supplied in multiple capsule strengths, typically ranging from 5 mg up to 250 mg. The availability of multiple strengths reflects the protocol requirements.

Q: Is Temozolomide Hexal the same as Temodar?

A: Temozolomide Hexal is the generic version of the medicine that contains the same active ingredient, temozolomide. Official documents confirm it is considered bioequivalent to the reference brand-name product, which is Temodar. This designation means they contain the identical active substance and are considered therapeutically equivalent.

Q: Are there any common foods or supplements that interact with Temozolomide Hexal?

A: Regulatory information primarily emphasizes the critical rule to take the medicine while fasting (on an empty stomach) to prevent a reduction in absorption. While specific interactions with most common foods or general supplements are not listed, an interaction with the seizure medicine Valproic Acid is noted, which can slightly affect the drug’s clearance.

Q: Is Temozolomide Hexal safe for older people (the elderly)?

A: Official labeling notes that the medicine has been studied and documented for use in elderly patients (those over 70 years). However, this population may have an increased risk of severe reductions in blood cell counts, specifically neutropenia and thrombocytopenia, compared to younger adults.

Q: Can I take pain relievers like ibuprofen or paracetamol with Temozolomide Hexal?

A: The official interaction documents do not explicitly detail interactions with common over-the-counter pain relievers. Official documentation notes that caution is required when taking any other medicines that may contribute to the suppression of blood cell counts (myelosuppression).

Q: Can Temozolomide Hexal cause changes in skin color or sensitivity to the sun?

A: According to the documented adverse reaction profile, it is indicated that some patients have reported photosensitivity reactions, which involve increased sensitivity to sunlight. Additionally, abnormal pigmentation (changes in skin color) has also been noted as an uncommon adverse effect.

Q: Are there specific symptoms that require immediate medical attention while taking Temozolomide Hexal?

A: Official warnings emphasize vigilance for symptoms related to the serious risks, such as severe myelosuppression or fatal hepatic injury. Signs that are noted as requiring attention include fever, unusual bruising or bleeding, yellowing of the skin or eyes, dark urine, or severe abdominal pain. These symptoms are related to the serious risks described in the labeling.

Q: What impact does Temozolomide Hexal have on fertility?

A: Regulatory documents state that the medicine may cause fetal harm, requiring females of reproductive potential to use effective contraception. The labeling indicates that male patients have been advised of the potential for irreversible infertility and the option of seeking advice regarding sperm preservation.

Q: Does Temozolomide Hexal affect the nervous system, leading to confusion or memory issues?

A: Yes, adverse reactions that affect the nervous system have been documented in regulatory sources. These include common effects like headache and less common issues such as dizziness, amnesia (memory loss), confusion, and convulsions (seizures).

Q: Are there any documented cases of resistance developing to Temozolomide Hexal over time?

A: Official documents discuss how the medicine's effectiveness can be limited by the presence of the MGMT enzyme in tumor cells. This enzyme acts as a counter-mechanism that reduces the drug's effect and is considered a key factor in both the tumor's intrinsic and acquired resistance to the therapy.

Q: Do clinical trials mention a maximum effective dose for Temozolomide Hexal?

A: In clinical trials, the dosage was often escalated up to 200 mg per square meter of body surface area daily for five consecutive days per cycle. Regulatory documents state that doses beyond this limit are often constrained by the potential for increased toxicity, especially effects on blood counts.

Q: Can patients who have had prior chemotherapy still use Temozolomide Hexal?

A: Official indications for use include patients with malignant glioma that is recurrent or has progressed after standard therapy. This means the medicine is generally indicated for use in individuals whose condition has returned or worsened following previous treatments, which may involve prior chemotherapy.

Q: Are there any specific vaccines to avoid while taking Temozolomide Hexal?

A: Due to the medicine's effect on the immune system, regulatory information states that the use of live vaccines is generally not recommended during treatment. This restriction is in place because of the increased potential risk of infection.

Storage and Disposal Requirements for Temozolomide Hexal Capsules

Storage Conditions: Temozolomide capsules must be stored at a temperature not exceeding 25 C to maintain stability. The product must remain in its original container and be kept tightly closed to protect the contents. Due to toxicity, the medicine must be stored strictly out of the sight and reach of children, as accidental ingestion can be fatal.

Handling and Disposal: The capsules must not be opened, chewed, or dissolved. If the contents contact the skin or mucous membranes, the exposed area must be washed immediately with soap and water. As an antineoplastic agent, the unused product and waste material must be managed according to local requirements for proper handling and disposal of anticancer drugs. It must not be disposed of via wastewater or regular household waste.